Beijing Aosaikang Pharmaceutical (002755.SZ) released a profit forecast, with an estimated net profit of 150 million to 195 million yuan for the fiscal year 2024, turning losses into profits compared to the previous year.
Auscon (002755.SZ) released its performance forecast for 2024, expecting the full-year attributable to the listed company's stock...
Beijing Aosaikang Pharmaceutical (002755.SZ) released its 2024 performance forecast, expecting a net profit attributable to shareholders of the listed company of 150 million to 195 million yuan for the full year, turning losses into profits year-on-year. During the reporting period, the company's sales of anti-infection and chronic disease products grew rapidly, with its operating revenue increasing year-on-year and profitability further improving.
Related Articles
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.
CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.
On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.
CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.
On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
RECOMMEND
General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025
Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025
Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025
